Chemoradiation Increases PD-L1 Expression in Certain Melanoma and Glioblastoma Cells

Immunotherapy approaches currently make their way into the clinics to improve the outcome of standard radiochemotherapy (RCT). The programed cell death receptor ligand 1 (PD-L1) is one possible target that, upon blockade, allows T cell-dependent antitumor immune responses to be executed. To date, it...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Front Immunol
Autores principales: Derer, Anja, Spiljar, Martina, Bäumler, Monika, Hecht, Markus, Fietkau, Rainer, Frey, Benjamin, Gaipl, Udo S.
Formato: Artigo
Lenguaje:Inglês
Publicado: Frontiers Media S.A. 2016
Materias:
Immunology
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5177615/
https://ncbi.nlm.nih.gov/pubmed/28066420
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2016.00610
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares